Quintiles Transnational enter into marketing agreement with Allergan for SANCTURA XR

Sep 28 2009

Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR^® (trospium chloride extended release capsules), an anticholinergic approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency, predominantly to primary care physicians in the United States.

Under the terms of the agreement, Quintiles will leverage its expertise in the primary care channel to rapidly deploy a specialized sales force to detail SANCTURA XR^® until December 31, 2011. Allergan will continue its promotion of SANCTURA XR^® in the urology specialty channel using its existing sales force. As part of the agreement, Quintiles will recruit and hire the new sales force, maintain responsibility for its performance and contribute to Allergan’s investment in consumer and professional marketing. Allergan will continue to record all sales of SANCTURA XR^® to physicians and provide royalty payments to Quintiles through the end of 2013.

"This strategic partnership will allow us to maximize our sales and marketing support for SANCTURA XR^® by extending our own sales force capacity and establishing our presence in the primary care channel so that we can reach more patients and fully realize the value of this important medication,” said Julian Gangolli, Allergan’s Corporate Vice President and President, North America.

"In today’s rapidly changing pharmaceutical environment, a greater number of companies are realizing the benefits of strategic partnerships to communicate with and educate physicians and patients in a targeted and cost-efficient manner,” said Ron Wooten, Executive Vice President, Corporate Development of Quintiles. “Allergan and Quintiles are innovators in the life sciences industry, leveraging our core competencies and resources to improve patients’ lives and achieve commercial success to continue investing in scientific advancements. We look forward to partnering with Allergan in offering SANCTURA XR^® to primary care physicians.”